AP
KITE

AHL Partners’s Kite Pharma, Inc. KITE Stock Holding History

AHL Partners’s Portfolio KITE Stock Details KITE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-5,497
Closed -$307K – 1284
2016
Q3 		$307K Buy
+5,497
New +$306K 0.01% 978

Other funds holding KITE

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

AHL Partners's KITE Position: Q4 2016 in Review

AHL Partners sold out of Kite Pharma, Inc. (KITE) in Q4 2016, closing a stake of 5,497 shares — an estimated $307K sold.

AHL Partners first reported a position in KITE in Q3 2016 and held it in 1 quarter. The position peaked at $307K in Q3 2016. 184 funds tracked by Wall St. Rank hold KITE as of Q4 2016.

  • AHL Partners reported no remaining Kite Pharma, Inc. position as of Q4 2016 after selling out during the quarter.
  • AHL Partners sold 5,497 Kite Pharma, Inc. shares in Q4 2016, an estimated $307K.
  • AHL Partners first reported a position in Kite Pharma, Inc. in Q3 2016 and held it in 1 quarter.
  • AHL Partners's Kite Pharma, Inc. position peaked at $307K in Q3 2016.
  • 184 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q4 2016.

Based on AHL Partners's 13F filing for Q4 2016, filed 14 Feb 2017.